UK markets closed
NIKKEI 225
38,202.37 -632.73 (-1.63%) HANG SENG
18,313.86 -165.51 (-0.90%) CRUDE OIL
79.12 +0.74 (+0.94%) GOLD FUTURES
2,320.40 -3.80 (-0.16%) DOW
39,016.68 +132.42 (+0.34%) Bitcoin GBP
50,011.65 -553.38 (-1.09%)
Newron Pharmaceuticals S.p.A. (NWPHF)
Other OTC - Other OTC Delayed price. Currency in USD
Add to watchlist
As of 01:08PM EDT. Market open.
| Previous close | 11.40 |
| Open | 11.40 |
| Bid | N/A x N/A |
| Ask | N/A x N/A |
| Day's range | 11.40 - 11.40 |
| 52-week range | 5.22 - 11.40 |
| Volume | |
| Avg. volume | 1,000 |
| Market cap | N/A |
| Beta (5Y monthly) | 0.70 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- Business Wire
Newron Announces Positive Top-line Results From Potentially Pivotal Phase II/III Study 008A With Evenamide in Schizophrenia Patients
MILAN, April 30, 2024--Newron announces positive top-line results from potentially pivotal Phase II/III study 008A with evenamide in schizophrenia patients
- Business Wire
Data from Newron’s study 014/015 and an evenamide clinical development outlook presented at the 2024 Annual Congress of the Schizophrenia International Research Society (SIRS)
MILAN, April 08, 2024--Newron presents existing evenamide study 014/015 data and future clinical development outlook for evenamide at 2024 SIRS Congress in Florence, Italy
- Business Wire
Newron Presents 2023 Financial Results and Provides 2024 Outlook
MILAN, March 19, 2024--Newron Pharmaceuticals announces 2023 year-end financial results and provides 2024 business outlook.
© 2024 Yahoo. All rights reserved.